Calciphylaxis most commonly occurs in
end-stage kidney patients and sometimes in earlier stages of chronic kidney
disease. Almost always fatal, calciphylaxis causes chronic non-healing of
wounds and affects up to 4% of all dialysis patients.
The Calciphylaxis Market is anticipated to reach USD 5,274.9
Million by 2030 at 11.3% CAGR during the forecast period 2022-2030.
According to the National Kidney
Foundation, close to 10% of the global population is afflicted with chronic
kidney disease (CKD). CKD has been found to be among the top causes of death,
and the increasing incidence of kidney disease is expected to resultant in the
increasing occurrence of calciphylaxis. At present, there is no diagnostic test
of the proper course of treatment for calciphylaxis, and instead, the condition
relies on clinical check-ups and prevention. As such, the demand for the
development of appropriate diagnostic and treatment options is expected to push
the market forward. Reportedly, obesity and diabetes are among the more common
risk factors which are highly prevalent today. These risk factors have
inevitably impacted the incidence of kidney diseases, particularly in developed
countries which are largely urban. Market players are expected to invest in
R&D toward the development of therapeutic options for calciphylaxis which
will undoubtedly offer the market with room for additional growth over the
course of the projection period.
Challenges present in the market which
impede growth include the high cost of existing treatment and the severe lack
of effective therapeutic options targetted at calciphylaxis.
Major Key
Players:
Some of the Calciphylaxis Market Players are Amgen Inc., Smith &
Nephew plc, Medtronics, 3M, BSN Medical, ConvaTec Inc, Sanifit, and others.
Segment Analysis
The global calciphylaxis market is segmented on the basis of
diagnosis, calciphylaxis treatment, and end user. On the basis of the
diagnosis, the calciphylaxis market is further segmented into deep skin
biopsies, blood tests, imaging, and others. The deep skin biopsies are further
segmented into shave biopsy, punch biopsy, and excisional biopsy. The blood
tests is further segmented into serum parathormone levels, blood glucose
levels, BUN (blood urea nitrogen), calcium levels, and others. Imaging is
further segmented into magnetic resonance imaging (MRI), CT scan, ultrasound,
and others. On the basis of the applications, the market is segmented into
intensive wound care, medication, therapy, clot-dissolving, and others.
Intensive wound care unit is further segmented into debridement, wet dressings,
and others. The medication is further segmented into cinacalcet, sodium
thiosulfate, steroids, and bisphosphonates. On the basis of end user, it is
segmented into hospitals, clinics, medical research centers, academic
institutes, and others.
Regional
Analysis
The
global calciphylaxis market consists of four regions the Americas,
Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for a major
share of the market owing to the presence of patient population, well-developed
technology, high healthcare expenditure and the presence of the leading
players. Moreover, due to the high prevalence of end stage renal diseases
(ESRD) on of the major cause of calciphylaxis in U.S. As per The Regents of the
University of California, the rate of ESRD is increasing in the U.S. by 5% per
year. The American calciphylaxis market is expected to reach USD 1,257 million
by 2023 from USD 581.9 million in 2016.
Europe consists of two regions
namely Western Europe and Eastern Europe. Western Europe consists of countries
namely Germany, the U.K., France, Italy, Spain, and Rest of Western Europe. Increasing
prevalence of cardiovascular calcification in ESRD patients is a key driver for
the growth of this market in Europe. Moreover, increasing healthcare
expenditure, rising research & development activities, awareness among
patients about the treatment options supporting the market growth for
calciphylaxis.
Asia Pacific consists of Japan,
China, India, Australia, Republic of Korea, and rest of Asia Pacific.
Increasing incidence of chronic kidney failure across Asia Pacific. Moreover,
the growth of this segment is attributed to high population growth, increasing
environmental pollution, and urbanization. Increasing incidence of
calciphylaxis, improving healthcare infrastructure and rising awareness about
the treatment process have spurred the growth of Asia Pacific region.
On the other hand, the Middle
East & Africa owns the minimum market share of the calciphylaxis market due
to less development in the healthcare services such as new and advanced
diagnosis & treatment methods in healthcare domain.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
